Compare Halliburton Company (HAL) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Natera Inc. Common Stock — how do they compare? Halliburton Company trades at $32.54 (market cap $27.32B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.1× Halliburton Company's market cap, and Halliburton Company pays a 2.07% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Natera Inc. Common Stock for 0 Days on average.
| HAL | NTRA | |
|---|---|---|
Market Cap | $27.32B | $57.03B |
Volume | 5,347,556 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $42.98 | $425.64 |
52-Week Low | $21.82 | $179.42 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $33.47B | $56.18B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.83, up 0.71% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a P/E of 17.17 and ROE of 14.89%, though 2025 net income declined to $1.28B from $2.5B in 2024. Recent developments include Venezuela energy agreements and a Cyprus deepwater contract win, positioning for international growth amid volatile oil markets.
Wall Street maintains strong bullish sentiment with 73% buy ratings and a $43.11 price target, representing 31% upside. Key risks include oil price volatility and execution challenges in new markets. The stock offers value with reasonable valuation metrics but faces near-term headwinds from declining profitability trends.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
